| Next 10 |
Ad
CYTO News and Press Altamira Therapeutics Ltd.
-
Nano-cap pharma Altamira Therapeutics ( NASDAQ: CYTO ) lost ~6% pre-market Friday after announcing plans to increase its authorized share capital to meet future funding needs and accommodate changes to a financing facility. The decision comes after FiveT Investment Management agreed t...
-
HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continues Strong data from Bentrio ® NASAR study reinforces its therapeutic benefit for allergic rhinitis Case for Bentrio’s protective effect in vira...
-
Altamira Therapeutics ( NASDAQ: CYTO ) is trading 26% down after the company said its therapy, Bentrio, to treat acute COVID-19, did not meet main goal in a trial. Top line data from the trial, dubbed Covamid, showed trend for more pronounced reduction in nasal viral...
-
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator NASAR main trial phase...
-
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhore TM platform’s functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs ...
-
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Provides Year - End 2022 Business Update Strategic Bentrio TM partnering or divestiture process enters decisive phase Partnering or divestiture process for inner ear therapeutics a...
-
Altamira Therapeutics ( NASDAQ: CYTO ) on Tuesday announced peer-reviewed publication of data that showed that its RNA delivery platform was an effective treatment for abdominal aortic aneurysm (AAA) in rodents. The peer-reviewed article was titled "Peptide-siRNA nanop...
-
Study results appeared in "Biomaterials Advances", a highly respected peer-reviewed journal, showcasing growing medical recognition of Company's patented RNA delivery platform for extrahepatic targets. Company's RNA delivery platform demonstrated effectiveness in mitigating abdominal a...
-
Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses HAMILTON, BERMUDA / ACCESSWIRE / June 29, 2022 / Altamira Therapeutics Ltd. ("the Company") (NASDAQ:CYTO ), a company ded...
-
Shares of Altamira Therapeutics (CYTO) are up 27% in premarket trading after the U.S. FDA granted 510(k) clearance to market nasal spray Bentrio for allergic rhinitis. Bentrio is a drug-free products that forms a thin layer on the n nasal mucosa to prevent allergens from coming on c...
Stock Information
Altamira Therapeutics Ltd. Company Name:
CYTO Stock Symbol:
NASDAQ Market:
Get CYTO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
